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Nucleosome acidic patch-targeting binuclear
ruthenium compounds induce aberrant chromatin
condensation
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The ‘acidic patch’ is a highly electronegative cleft on the histone H2A–H2B dimer in the
nucleosome. It is a fundamental motif for protein binding and chromatin dynamics, but the
cellular impact of targeting this potentially therapeutic site with exogenous molecules
remains unclear. Here, we characterize a family of binuclear ruthenium compounds that
selectively target the nucleosome acidic patch, generating intra-nucleosomal H2A-H2B
cross-links as well as inter-nucleosomal cross-links. In contrast to cisplatin or the progenitor
RAPTA-C anticancer drugs, the binuclear agents neither arrest speciﬁc cell cycle phases nor
elicit DNA damage response, but rather induce an irreversible, anomalous state of condensed
chromatin that ultimately results in apoptosis. In vitro, the compounds induce misfolding of
chromatin ﬁbre and block the binding of the regulator of chromatin condensation 1 (RCC1)
acidic patch-binding protein. This family of chromatin-modifying molecules has potential for
applications in drug development and as tools for chromatin research.
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H istone proteins package eukaryotic DNA into chromatin,yielding a structural hierarchy, in which nucleosomescomprise the basic repeating units1. Each nucleosome
consists of a core region, composed of ~146 bp wrapped around a
histone octamer, which comprises two copies each of four dif-
ferent core histone proteins. The H3–H4 histone tetramer orga-
nizes largely the central DNA of the nucleosome core, while the
two H2A–H2B histone dimers organize the outer DNA regions.
Outside of the core region, each nucleosome harbours a variable
length of linker DNA, typically 10–90 bp, which can be associated
with a ﬁfth type of histone protein, linker histone.
There are at least six distinct epigenetic features of chromatin
that are modulated in a site-speciﬁc and cell state-dependent
manner to achieve precise control of genomic activities, notably
transcription. These entail mostly attributes that relate to indi-
vidual nucleosomes, including histone octamer occupancy/posi-
tioning on the double helix and an enormity of potential post-
translational modiﬁcations to the histone proteins, in addition to
substitutions with different histone variants and methylation of
the DNA2, 3. Moreover, histone composition and DNA sequence
can also impact nucleosome stability and dynamics properties4, 5.
An additional epigenetic feature of chromatin regulatory struc-
ture entails consolidation of nucleosomes into higher states of
compaction through linker histone association.
The pronounced changes in the gene expression proﬁles that
yield different cell types and states means that there are a mul-
titude of epigenetic distinctions in chromatin, which underlie
disease and differentiation. In cancer cells for instance, aberrant
nucleosome occupancy, histone post-translational modiﬁcations
and DNA methylation work in unison to silence tumour sup-
pressor genes while activating other genes that enable tumour
development and progression2, 3. This suggests the possibility that
compounds capable of recognizing distinguishing structural or
chemical features of chromatin could allow the targeting of vul-
nerable points in cancer cells6. But on top of this, studying such
compounds can also provide basic insights into molecular
recognition and chromatin activity7–9.
In studying metal-based anticancer agents that were initially
expected to act therapeutically by forming DNA adducts, we had
found that certain ruthenium and osmium compounds have in
fact a preference to form adducts at deﬁned histone protein sites
in the nucleosome10, 11. This had prompted us to explore further
the activities of histone-associating metalloagents as they can
have certain advantages over purely organic compounds. Heavy
metal centres allow distinct characteristics of coordination geo-
metry, oxidation state and ligand exchange for ﬁne-tuning reac-
tivity and afﬁnity properties of the compound12, and whether one
is focused on the structural biology, biochemistry or cellular
localization, the presence of heavy atoms can make visualization
and quantiﬁcation more accessible.
The RAPTA [(η6-arene)Ru(PTA)Cl2] (PTA= 1,3,5-triaza-7-
phosphaadamantane) antimetastasis, antitumour and anti-
angiogenic compounds13–15 have shown promise for use in
chromatin research as they have a proclivity to generate protein
adducts in cellular chromatin7. Steric access limitations to the
ruthenium centre from the presence of both arene and PTA
ligands disfavours DNA adduct formation7, with RAPTA adducts
forming in the nucleosome core mainly at two adjacent sites, RU1
and RU2, within a highly electronegative cleft region on the
surface of the H2A–H2B dimer9, 10. This region, known as the
acidic patch because it comprises a preponderance of glutamate/
aspartate residues, coincides with a key binding platform for
nuclear factor association and chromatin compaction1, 16, 17.
Given the distinct cellular impact and molecular targeting
properties of the RAPTA compounds7, 9, 10, 13–15, here we
investigate the activity of binuclear compounds that are
composed of two RAPTA groups connected by various linker
moieties, which could allow a stronger and more speciﬁc inter-
action with the nucleosome acidic patch. Initial characterization
of binuclears synthesized with short linkers showed that their
cellular cytotoxicity is much elevated over the mononuclear form
and is in turn greatest with the most conformationally con-
strained (rigid) linkers18. In this work, we study these and
additional binuclear agents synthesized with long linker moieties.
We ﬁnd that the binuclears are selective for the RU1/RU2 sites in
the nucleosome acidic patch, generate substantial quantities of
adducts in cellular chromatin but do not elicit a DNA damage
response, and give rise to an unusual mode of cell killing asso-
ciated with an irreversible state of aberrant chromatin con-
densation. This implies that acidic patch-targeting metalloagents
could have potential for applications in chromatin studies and in
the development of therapeutic compounds.
Results
Binuclear ruthenium compounds. The binuclear agents were
synthesized through amide-forming reactions between mono-
nuclear ruthenium arene carboxylic acid [(toluene-p-propionic
acid)Ru(1,3,5-triaza-7-phosphaadamantane)X] (X= Cl2 or oxa-
late) and diamine compounds with diverse substituents linking
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Fig. 1 Structures and cytotoxicity parameters of compounds used
throughout the study. Cell growth inhibition, IC50, values (μM; HeLa cells,
40 h) are shown (mean± s.d., n= 3)
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the amine groups18 (Fig. 1; Supplementary Figs. 1–5). We gen-
erated two distinct classes of binuclears with either rigid 1,2-
diphenylethylenediamide linkers, yielding three stereochemically
distinct species (RR, SS, RS), or ﬂexible methylene or polyethylene
glycol amide linkers. In the latter category, we characterized three
compounds: one with a short, 2-methylene spacer (C2) and two
others with long linkers, 10-unit methylene (C10) and 13-unit
polyethylene glycol (PEG).
Selective for the nucleosome acidic patch. To assess the
nucleosome site selectivity of the binuclear agents, we carried out
X-ray structural characterization of nucleosome core particle
(NCP) crystals incubated with each of the compounds (Supple-
mentary Tables 1–4). This included NCP treatments with six
chlorido and ﬁve oxalato compounds at different concentrations
and durations. For all of the chlorido agents, substantial adduct
formation is observed ﬁrst at the RU1 site, entailing bifunctional
coordination of the ruthenium cation by the E61 and E64 side
chains of H2A (Fig. 2; Supplementary Figs. 6–8; Supplementary
Table 4). For the RR, SS, C2, C10 and PEG agents, high occu-
pancy of the RU1 site is proceeded by substantial adduct gen-
eration at the RU2 site, entailing bifunctional coordination of the
ruthenium cation by the E102 and H106 side chains of H2B. This
coincides with the same adduct formation proﬁle observed for the
mononuclear RAPTA drugs, wherein RU1 is favoured as the
initial site of adduct formation, which in turn fosters adduct
generation at the adjacent RU2 site by providing an additional
hydrophobic interaction surface for the carrier ligands9, 10. In
contrast to the chlorido agents, none of the oxalato compounds
yield evidence of adduct formation at any sites on the NCP.
Therefore, the aquation of these agents is too slow under the
crystal buffer conditions, rendering them unreactive, and we thus
only pursued the chlorido agents further.
For the three agents with ﬂexible linkers—C2, C10 and PEG—
little additional electron density is observed beyond that
corresponding to the two RAPTA groups (Supplementary Fig. 7).
On the other hand, for the three compounds with rigid linkers—
RR, SS and RS—there is electron density between the two RAPTA
groups, consistent with the linker moiety (Supplementary Figs. 6
and 8). For the RR and SS isomers, the two RAPTA groups are
positioned side by side on one face of the diphenyl linker, whereas
for the RS isomer, the RAPTA groups are situated instead on
opposing faces of the diphenyl linker18. This differential
conﬁguration allows the RR and SS agents to form bridging
adducts at the RU1 and RU2 sites, thereby cross-linking the H2A
and H2B histones (Fig. 2c). However, subsequent to coordination
of the ﬁrst ruthenium ion of the RS agent at RU1, the second
ruthenium ion is correspondingly locked out of position to allow
coordination at the adjacent RU2 site. Instead, the open, extended
conformation of RS fosters coordination of the second ruthenium
ion at a more distant histone site, the E91 side chain of H2A
(Supplementary Fig. 8b).
In addition to the primary RU1 and H2A E91 sites, there is
some slight degree of adduct generation by RS apparent at the
RU2 site, but this must coincide with reaction of a second RS
molecule, given the stereochemical constraints of the linker
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Fig. 2 X-ray crystal structures of binuclear-treated NCP. a Overview of NCP with an RR adduct (space ﬁlling representation) in the acidic patch. Histone
proteins are coloured cyan (H3), green (H4), yellow (H2A) and salmon (H2B), and the two DNA strands are shown in different colours. Twofold axis of
pseudo-symmetry is indicated (arrow). b View of one face of the nucleosome core with an RR adduct. The histone octamer is rendered with an
electrostatic potential surface (red, negative; blue, positive) to emphasize the acidic patch. c, d Close up views of histone interactions with the RR (c) or the
C2 (d) adduct
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(Supplementary Fig. 8b). As such, this implies that coordination
of a second binuclear molecule at RU2 is sterically disfavoured
subsequent to occupation of the RU1 site by the ﬁrst molecule.
Moreover, subsequent intramolecular chelation at RU2 should be
favoured on entropic grounds, as long as this is permitted by the
linker conﬁguration. In this regard, modelling of the C2 structure
shows that even the shortest linker would allow RU1-RU2 cross-
linking (Fig. 2d). It is therefore likely that the majority of adducts
in the crystal structures for C2, C10, PEG, RR and SS are bridging
RU1-RU2 cross-links, and the lack of clarity in the connecting
electron density a consequence of linker ﬂexibility.
Generate substantial chromatin adducts in cells. To further
analyse the targeting and impact of the binuclears, we focused on
a subset of the RU1-RU2 cross-linking agents, consisting of the
one with the short ﬂexible linker (C2), the two with the longest
linkers (C10, PEG), each of which has a distinct linker chemistry,
and one with a rigid linker (RR). Comparison of cell growth
inhibition values (Fig. 1) shows that the four binuclears are all
substantially more cytotoxic than the mononuclear RAPTA
progenitor drug (RAPTA-C; C= cymene), spanning a range of
about sixfold (PEG) to 64-fold (C10) greater cytotoxicity.
Moreover, the most potent compounds tested, C10 and RR, are
roughly as cytotoxic as the classic DNA cross-linking drug,
cisplatin.
We next quantiﬁed cellular uptake and chromatin adduct
formation for the different agents, which shows that these
parameters are roughly proportional to the treatment
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Fig. 3 Quantiﬁcation of cellular uptake and chromatin binding of binuclears and mononuclear RAPTA drug. a, b Cells were treated with binuclear agent or
RAPTA-C (RAPTA) either at concentrations corresponding to their respective IC50 values (Fig. 1; mean± s.d., n= 3; a) or at an equimolar concentration of
100 μM (b; mean± s.d., n= 3). Ruthenium levels were determined by inductively coupled plasma-mass spectrometry. c Chromatin selectivity is expressed
as the fraction of the total agent taken up by the cell that is chromatin-associated (chromatin adducts/total cell uptake) for either the IC50 (left) or 100 μM
(right) treatments (mean± s.d., n= 3)
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concentration for the binuclears (Fig. 3). That is, the lower
treatment concentration or IC50 value corresponds to lesser
uptake and fewer resulting chromatin adducts, and when cells are
treated with equimolar agent concentrations (100 μM), roughly
similar levels of uptake and chromatin binding for the binuclears
are achieved. Moreover, for both the binuclears and RAPTA-C,
the level of chromatin adducts formed is rather proportional to
the amount of compound taken up by the cell. In contrast,
however, the uptake and chromatin targeting efﬁciency of the
four binuclears is generally much greater than that of RAPTA-C
as indicated by the higher values achieved in the equimolar
concentration treatments (Fig. 3b). In terms of the intracellular
chromatin site selectivity, the fraction of ruthenium taken up by
the cell that associates with chromatin is signiﬁcantly higher for
the binuclears compared to RAPTA-C for the IC50 treatments
(ranging from 8 to 23% vs. 6%), whereas this parameter is nearly
constant for the equimolar treatments (spanning a narrower
range of 8–11%; Fig. 3c).
Absence of DNA damage response. Given the greater chromatin
targeting activity of the binuclears over the mononuclear RAPTA
agent, we conducted cell cycle and response analysis to assess
overall impact and in particular whether the binuclears generate
any signiﬁcant degree of DNA adducts. For the cell cycle analysis,
cells were treated for 40 h at the IC50 concentrations (Fig. 1) of
the compounds to ensure subjection of a severe and uniform level
of trauma. Nonetheless, the cell cycle proﬁles of the four binuc-
lears are, within statistical error, identical to that of the untreated
cells (Fig. 4; Supplementary Fig. 9). In contrast, the RAPTA-C-
treated cells elicit a substantial degree of arrest in both the S and
G2/M phases. This suggests that the binuclears do not yield sig-
niﬁcant levels of DNA adducts, as this would otherwise be
expected to cause inhibition of DNA replication or transcription,
resulting in stalling at S or G2/M. On the other hand, we had
previously shown that a minor fraction of chromatin-associated
RAPTA-C adducts pertain to DNA binding7, which could
rationalize the cell cycle impact we observe here.
To further substantiate that the binuclears do not target the
DNA, we conducted western blot analysis for DNA damage
markers (Supplementary Figs. 10 and 11). This indicates a slight
degree of DNA damage response from RAPTA-C-treated cells
relative to the strong effect stemming from cisplatin treatment. In
contrast, treatment with the most cytotoxic binuclear com-
pounds, C10 and RR, yields DNA damage signals that are no
greater than that of the untreated control cells (background level).
Induce aberrant chromatin condensation in cells. Considering
the lack of impact on the cell cycle and the absence of DNA
damage response and apparent DNA targeting, in spite of cis-
platin-like cytotoxicity for some of the binuclear agents, we
wanted to understand how these compounds induce cell death.
We set up a live cell imaging system, where cells had been stably
transfected with an H2B-EGFP (H2B histone fused with
enhanced green ﬂuorescent protein) plasmid that allows visuali-
zation of chromatin. In this way, we followed nuclear activity over
the course of 24 h subsequent to pre-treatment with either one of
the binuclears, RAPTA-C or cisplatin (Fig. 5; Supplementary
Movies 1–7). For untreated cells, division is observed to proceed
in regular fashion, with the start and completion of mitosis taking
place in under 1 h.
For samples treated with cisplatin, cells are typically observed
to transform from a normal appearing nucleus suddenly into the
apoptotic state. In the case of RAPTA-C treatment, cells appear to
spend an extended time in mitosis before undergoing apoptosis.
In contrast, the binuclear agents are seen to induce an irreversible,
condensed state of chromatin, with a degree of compaction that
appears similar to that of the untreated mitotic cells. This state of
aberrant chromatin condensation persists for many hours before
apoptosis.
Induce spontaneous misfolding of chromatin ﬁbre. Testing the
inﬂuence of the binuclear agents on chromatin dynamics in vitro
could shed light on the striking nuclear impact of these com-
pounds in inducing an irreversible condensed state of the chro-
matin. For this, we utilized a nucleosome array system consisting
of thirty-six 177 bp nucleosomes in tandem (Supplementary
Fig. 12), which serves as a model for chromatin ﬁbre19. Native
electrophoretic mobility shift assays indicate that adducts formed
by the binuclears induce compaction (folding) of the nucleosome
array, to a degree that is proportional to treatment strength
(Fig. 6). That is, in spite of the added positive charge and
increased molecular weight from the binuclear adducts, the
treated array migrates faster than untreated array, indicative of a
more compact conﬁguration. In contrast, the opposite effect is
seen for sub-nucleosomal histone-DNA assemblies (present to
ensure integrity of the reconstituted array), which accumulate
adducts as well, but migrate more slowly as a consequence. Cis-
platin treatment of array yields little or no apparent compaction,
whereas treatment with RAPTA-C does induce some extent of
array folding, but only at high treatment concentration and to a
reduced degree compared to the binuclears. In fact, high con-
centration binuclear treatment results in aggregation and pre-
cipitation of the array.
To further understand the effects of binuclear adducts on
chromatin ﬁbre, we carried out electron microscopic (EM)
analysis of the array (Fig. 7). In the native state, under low ionic
strength conditions, the array remains unfolded, adopting a
random-coil, beads-on-a-string conformation. In the presence of
divalent metal, at around 1.6 mM Mg2+, the array achieves a state
of maximal intramolecular compaction, yielding the so-called
two-start helix conﬁguration, in which nucleosomes ‘zig-zag’
along a left-handed axis20.
In contrast to the behaviour of native material, binuclear-
treated array adopts a highly compact conﬁguration in the
absence of any Mg2+ (low ionic strength; Fig. 7; Supplementary
Fig. 13). The degree of compaction appears similar to that of
Mg2+-folded native array, and the addition of Mg2+ to the
binuclear-treated samples does not yield any further compaction.
Moreover, the compact binuclear conﬁguration achieved is highly
distinct relative to native material, being varied from one
molecule to the next, overall irregular and displaying greater
S G0/G1 G2/M 
0% 20% 40%
Fraction of cell population
60% 80% 100%
Untreated
C2
C10
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RR
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Fig. 4 Cell cycle analysis of binuclear and mononuclear RAPTA drug-
treated cells. Cell cycle proﬁles are based on analysis of cultured tumour
cells by ﬂow cytometry (mean± s.d., n= 6)
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twisting and bending along the axis. Nonetheless, imaging of
cisplatin- or RAPTA-C-treated array under Mg2+-free conditions
yields no pronounced compaction effect, although a slight degree
of RAPTA-C-induced folding or structural perturbation is
discernible (Supplementary Fig. 13).
Impede protein binding and cross-link nucleosomes. Since the
nucleosome acidic patch is known to play a key role in nuclear
factor binding and chromatin ﬁbre folding1, 16, 17, we investigated
how the binuclear adducts may inﬂuence interactions with the
nucleosome core. We tested the effect of binuclear and RAPTA-C
treatments on the NCP binding of the acidic patch-associating
protein, regulator of chromatin condensation 1 (RCC1)21. The
binuclear adducts are able to inhibit or completely block the
binding of RCC1, while the RAPTA-C samples, subjected to the
same treatment concentrations as the binuclears, do not show
binding interference (Fig. 8a). Nonetheless, at high treatment
strength, RAPTA-C is able to completely block RCC1 binding to
the NCP (Fig. 8b).
For the RCC1 binding analysis, we used short compound
incubation times to minimize precipitation of the derivatized
NCP. When NCP was subjected to a longer incubation time with
the binuclears, extensive internucleosomal cross-linking is
apparent, resulting in precipitation at the higher treatment
concentrations (Fig. 8c). In contrast, for the mononuclear
RAPTA drug, nucleosome-nucleosome cross-linking is not
observed. Consistent with this, denaturing electrophoretic gel
analysis shows distinct cross-linked histone species formed by the
binuclears compared to RAPTA-C (Supplementary Fig. 14),
although the harsh conditions required to denature the nucleo-
some are likely to also alter ruthenium adducts to at least some
degree.
Discussion
The RAPTA-based binuclear agents characterized here display
the striking ability to induce a catastrophic state of chromatin
condensation, which persists for many hours and ultimately
coincides with cell death. The extent of condensation is similar to
that of mitotic chromosomes, but nonetheless cells are not able to
recover from this compacted state once attained. The in vitro and
cellular analyses suggest that the phenomenon arises from the
nucleosome acidic patch-targeting activity of the binuclears.
Indeed, there appears to be no signiﬁcant DNA binding in the
cell, although the binuclears efﬁciently generate adducts on cel-
lular chromatin, there is neither a measurable impact on cell cycle
proﬁle nor elicitation of a DNA damage response.
We had previously characterized RAPTA-C binding by
IC50-concentration treatment of A2780 ovarian cancer cells and
Untreated 
02:00:00 02:10:00 02:20:00 02:30:00 02:40:00 02:50:00
cisplatin
PEG 
C2
RR
C10
RAPTA-C
10 µm 
10:30:00 10:40:00 10:50:00 11:00:00 11:10:00 11:20:00
16:30:00 16:40:00 16:50:00 17:20:00 18:00:00 18:50:00
04:30:00 05:00:00 05:30:00 06:20:00 07:20:00 10:20:00
08:00:00 09:10:00 09:30:00 10:00:00 11:20:00 21:30:00
03:40:00 03:50:00 04:20:00 04:40:00 05:40:00 08:40:00
19:40:00 19:50:00 20:00:00 20:10:00 20:40:00 23:40:00
Fig. 5 Live ﬂuorescence imaging of drug- and binuclear-treated cells. Nuclear chromatin is visible by virtue of the incorporated H2B-EGFP histone fusion
protein. Montages correspond to extractions from the 24 h imaging sequences (Supplementary Movies 1–7; times shown at bottom for each frame)
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determined that ~4% of the intracellular ruthenium content is
associated with chromatin7, 10. A similar degree of chromatin site
selectivity is apparent for the classic DNA-targeting agent cis-
platin22. In the present study, we observe a somewhat higher level
of site preference for chromatin in HeLa cells, at respectively, 6%
or 9%, depending on whether cells are treated with an IC50 or
100 μM concentration of RAPTA-C. Substantial chromatin
adduct levels would rationalize the activity observed here with the
cell imaging experiments, whereby RAPTA-C is seen to induce
apoptosis by interfering with the mitotic process. This is more-
over consistent with the substantial degree of G2/M phase arrest
caused by this drug, as seen in this study and previously7 for
different cancer cell types. Indeed, a recent investigation found
that RAPTA-C induces increased formation of DNA bridges in
cancer cells23, which is consistent with its partial DNA-targeting
activity7 and could help further rationalize the distinct cellular
impact we observe here. Nonetheless, the binuclear activities are
decisively different from those of this progenitor mononuclear
RAPTA drug and their chromatin targeting abilities are also
superior, both in terms of more efﬁcient cellular uptake and
chromatin adduct formation, as well as overall greater intracel-
lular localization to chromatin.
The crystallographic studies show that all of the binuclears,
with the exception of the ‘locked-out’ RS18, are capable of
forming bridging adducts at sites RU1 and RU2, consequently
cross-linking H2A and H2B within the dimer. On the other hand,
binuclear treatments of NCP in solution yield inter-nucleosomal
cross-links, which are presumably acidic patch-acidic patch
(RU1–RU1; H2A–H2A) cross-linking. Although we do not
observe such cross-links in the NCP crystals, the crystal packing
conﬁguration and site-blocking inter-particle contacts would
necessitate a binuclear linker length on the order of 100 Å or so to
allow these to form (the fully extended conformation of our
longest binuclear, PEG, coincides with a Ru-Ru separation of ~32
Å). Nonetheless in the solution state, where nucleosomal inter-
actions are dynamic, even the shortest binuclear agents, RR and
C2, are effective at cross-linking nucleosomes. Since this is a
property that is not observed for the progenitor mononuclear
RAPTA drug, it may rationalize the higher cytotoxicities of the
binuclears and moreover contribute to their nucleosome array
misfolding activity in vitro and anomalous chromatin condensing
activity in the cell. At the same time, however, the broad range of
cytotoxicity displayed by PEG, C2, RR and C10 indicates an
important role of linker ﬂexibility18, length and also possibly
chemical nature, in modulating cellular impact. It is interesting to
speculate that these features may inﬂuence chromatin binding
and cross-linking activity in a structure-/site-speciﬁc fashion to
yield differential cytotoxic effects. However, at present we cannot
rule out the possibility of other functionally important cellular
protein targets. In any case, we show here that the binuclear and
RAPTA-C adducts are also capable of inhibiting the binding of
RCC1 and seemingly other acidic patch-binding nuclear
proteins9, 16, and this is likely to contribute to their cellular
impact.
In addition to the cross-linking activity, another feature of
acidic patch association that likely contributes to the chromatin
compacting activity of the binuclears relates to electrostatic and
surface contour effects of the adducts. Indeed, we observe a
modest degree of nucleosome array folding ability with the
mononuclear RAPTA drug, which does not show any
nucleosome-nucleosome cross-linking activity. Studies have
demonstrated that the acidic patch plays a key function in
chromatin ﬁbre compaction, and the binding of protein factors to
this region can modulate chromatin structure and dynamics17, 24,
25. In particular, the effect of the binuclears appears to be ana-
logous to that of the acidic patch-targeting viral peptide, LANA26.
The 23-amino acid LANA peptide promotes Mg2+-induced
folding and aggregation of nucleosome array and contributes a 4+
charge24 to the acidic patch, like the binuclear adducts. Moreover,
the LANA peptide also alters nuclear architecture and chromatin
condensation in cells. Nonetheless, unlike the LANA peptide, the
binuclears are capable of inducing seemingly full, albeit aberrant,
compaction in vitro under Mg2+-free conditions and bring about
dramatic condensation in cells. This likely arises from the added
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Fig. 6 Electrophoretic mobility shift analysis of drug- and binuclear-treated nuclesosome array. Agarose gel samples include native array (un) and array
treated with either cisplatin (cisPt), PEG, RAPTA-C (RAP) or C2 (m, 500–10,000 bp DNA marker). Samples corresponding to equimolar high treatment
concentration between the four different agents are indicated with arrows. The maximal RAPTA-C and C2 treatments are at ﬁvefold higher concentration,
at which point all of the binuclear-treated material is lost to precipitation
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nucleosome cross-linking properties of the binuclears, since a
similar electrostatic impact could be achieved by either a single
LANA peptide molecule or saturating levels of RAPTA-C that
introduce the same 4+ charge into the acidic patch. Moreover, the
impact of peptide-acidic patch association can itself be varied, as
the cytomegalovirus IE1 C-terminal domain peptide has in fact
been shown to inhibit linker histone-induced folding of nucleo-
some array27. In this case, however, the peptide has a lower net
charge (3+) and binds the acidic patch with an aspartate and
carboxy-terminal element protruding into solvent space, which
could disfavour inter-nucleosomal interactions.
There are few previously reported exogenous ligands that are
known to target the acidic patch, including just several different
types of related Ru/Os-arene compounds7, 9–11, 28 and the natu-
rally occurring viral peptides. Compared to the viral peptides,
which like the binuclears are also polyvalent, the binuclears have
unprecedented activities in controlling chromatin structure and
compaction. These properties could potentially be exploited for
developing chromatin investigation tools or therapeutic agents.
For instance, it may be possible to design binuclears that are
selective for speciﬁc H2A variants, which differ with respect to
acidic patch charge distribution or structure. This could allow for
targeting particular chromatin sites and activity states. Moreover,
binuclear adducts are likely to accumulate in the nucleus at sites
where the acidic patch is unoccupied by protein factors. In the
NCP crystals, we observe adduct formation at just one of the two
symmetry-related acidic patches, as the other is effectively
blocked by a crystal contact involving the H4 N-terminal tail.
This type of interaction has been implicated in chromatin higher
order structure17, 29–31, suggesting that the H4 tail may sterically
block compounds from binding to the acidic patch in condensed
chromatin states, such as with silenced genes. In this way, the
binuclears may preferentially associate with open states of chro-
matin, in particular activated genes, although more work is
required to test this possibility. Conversely, once the acidic patch
is occupied with a binuclear adduct, it may block the binding or
alter the association mode of the H4 tail, which may underlie, at
least in part, the non-native structures observed for the binuclear-
compacted nucleosome array. Collectively, this suggests that
compounds in this binuclear ruthenium family could help to shed
light on cell type- and state-dependent distinctions in chromatin
structure and activity as well as provide possibilities for differ-
entially targeting the distinct chromatin landscape of cancer cells.
Methods
Binuclear compound synthesis. Reagents: All chemicals were used as received
from suppliers. 4,7,10-trioxa-1,13-tridecanediamine (97%) and 1,10-diaminode-
cane (97%), O-(benzotriazol-1-yl)-N,N,N′,N′-tetramethyluronium tetra-
ﬂuoroborate (97%), N,N-diisopropylethylamine (99%) and acetyl chloride (98%)
were purchased from Sigma-Aldrich. N,N-dimethylformamide (99.8%, extra dry,
Acroseal®), acetonitrile (99.9%, extra dry, Acroseal®) and acetone (99.8%, extra dry,
Acroseal®) were obtained from Acros Organics, and methanol (anhydrous, 99.8%)
was purchased from Sigma-Aldrich.
Untreated
−Mg2+
Untreated
+Mg2+
PEG
+Mg2+
PEG
–Mg2+
Fig. 7 Electron microscopy of negatively stained native and binuclear-treated nucleosome array. Samples include native array (untreated) with and without
1.6 mMMg2+ and PEG-treated array with and without 0.5 mM Mg2+ (binuclear-treated array aggregates/precipitates at higher Mg2+ concentrations). The
black scale bar inset corresponds to 100 nm
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NMR analysis: 1H, 13C and 31P nuclear magnetic resonance (NMR) spectra
were recorded on a Bruker Avance II 400 spectrometer (1H at 400MHz, 13C at 101
MHz and 31P at 162MHz). Spectra are referenced internally to residual solvent
peaks (D2O: 1H δ 4.79, 13C δ unreferenced; DMSO-d6: 1H δ 2.50, 13C δ 39.52); 31P
NMR spectra are reported relative to an 85% H3PO4 external reference.
Mass spectrometry analysis: A Q-Tof (Quadrupole Time-Of-Flight) Ultima
mass spectrometer (Waters) was utilized in the acquisition of electrospray-
ionization mass spectrometry (ESI-MS) data. The spectrometer was ﬁtted with a Z-
spray source and LockSpray interface and was operated in positive ionization
mode. Sample solutions were made in CH3CN:H2O:HCOOH (50:49.9:0.1) (~10−5
M) and were infused into the spectrometer (20 μl per min) with a mixture of
CH3CN:H2O:HCOOH (50:49.9:0.1). The capillary voltage was set at 3.5 kV, the
sample cone set at 35 V, the source temperature, and the desolvation temperatures
were set at 80 °C and 200 °C, respectively, and the acquisition window spanned m/z
300–1500 in 1 s. A phosphoric acid solution (0.01%), introduced via an orthogonal
ESI probe, was utilized as an external calibrant. A correction factor for the mass
scale was determined from LockSpray data to provide accurate mass information of
the analyte. MassLynx 4.1 software was used for data processing.
Elemental analysis: Elemental analysis was carried out using an EA1108
Elemental Analyzer (Fisons Instruments).
Synthesis overview: The overall approach for synthesizing the binuclear agents,
shown in Supplementary Fig. 15, is based on our previously reported method for
producing the chlorido and oxalato derivatives of C2, RR, SS and RS18. Below, we
describe the synthesis and analysis of the chlorido (Cl4) and oxalato (Ox)
derivatives of PEG and C10.
RuPEGOx: Ruthenium acid monomer (300 mg, 0.588 mmol) and O-
(benzotriazol-1-yl)-N,N,N′,N′-tetramethyluronium tetraﬂuoroborate (TBTU; 188
mg, 0.586 mmol) were suspended in N,N-dimethylformamide (DMF; 2.5 ml)
followed by the addition of N,N-diisopropylethylamine (DIPEA; 102 µl, 0.586
mmol). The yellow suspension was stirred for 10 m followed by the addition of
4,7,10-trioxa-1,13-tridecanediamine (58 µl, 0.265 mmol). The mixture was stirred
for 2 h under an atmosphere of N2 and then ﬁltered to isolate unreacted ruthenium
monomer acid. The collected yellow ﬁltrate was added dropwise to acetone (15 ml)
to yield a precipitate, and the suspension was diluted by the addition of MeCN (10
ml) and then sonicated for 5 min. The precipitate was isolated by ﬁltration to yield
a hydroscopic yellow solid, which was dried under high vacuum to yield the crude
product as a yellow hydroscopic solid that was utilized without further puriﬁcation
(200 mg, 0.166 mmol, 63%). 1H NMR (D2O, 400MHz): δ= 5.92–5.99 (m, 8H, Ar),
4.60 (s, 12H, PTA), 4.18 (s, 12H, PTA), 3.58–3.73 (m, 8H, O–CH2–CH2–O), 3.47
(t, J= 6.5 Hz, 4H, 2 × CH2), 3.21 (t, J= 6.5 Hz, 4H, 2 × CH2), 2.61 (s, 8H, 4 × CH2),
2.08 (s, 6H, CH3), 1.71 (p, J = 6.5 Hz, 4H, 2 × CH2–CH2–CH2); 31P{1H} NMR
(D2O, 162 MHz): δ=−33.2; 13C{1H} NMR (D2O, 101 MHz): δ = 173.8 (2C, amide
C=O), 166.1 (4C, oxalate C=O), 98.9 (2C, Ar(q)), 96.6 (2C, Ar(q)), 88.4 (d, 4C, J =
3.5 Hz, Ar), 87.7 (d, 4C, J = 4.0 Hz, Ar), 70.7 (d, 6C, J= 7.0 Hz, PTA), 69.6, 69.4,
68.3 (6C, 6 × CH2), 48.6 (d, 6C, J= 15.5 Hz, PTA), 36.4, 35.6, 28.3 (8C, 8 × CH2),
17.4 (2C, 2 × CH3); high resolution mass spectrometry (HRMS) (ES+) m/z found
604.1315 [M + 2H]2+ C46H70N8O13P2Ru2 requires 604.1325. See Supplementary
Fig. 2 for NMR spectral proﬁles.
RuPEGCl4 (PEG): RuPEGCl4 was synthesized using reported methodology via
RuPEGOx18. This entailed slow addition of acetyl chloride (890 μl, 12.5 mmol) to
MeOH (5ml) at 0 °C under an atmosphere of N2. The solution was allowed to stir
for 10 m followed by the addition of RuPEGOx (80 mg, 0.066 mmol) as a solution
in MeOH (2 ml). A red precipitate instantly formed; the mixture was further stirred
for 16 h. The solvent was then decanted and the oily red residue was washed with
MeOH (2 × 5 ml) and then dried under reduced pressure to yield the tetra-
hydrochloride salt of the desired product as a hydroscopic red solid (40 mg, 0.030
mmol, 45%). 1H NMR (DMSO-d6, 400MHz): δ= 7.93 (s br, 2H, amide NH),
5.82–5.96 (m br, 8H, Ar), 4.70–4.93 (m br, 12H, PTA), 4.29 (s br, 12H, PTA),
3.41–3.53 (m, 8H, –O–CH2–CH2–O–), 3.33 (m, 4H, 2 × CH2), 3.05 (m, 4H, 2 ×
CH2), 2.37 (s, 8H, 2 × –ArCH2CH2CO–), 1.91 (s, 6H, 2 × CH3), 1.58 (m, 4H, 2 ×
CH2–CH2–CH2); 31P{1H} NMR (DMSO-d6, 162MHz): δ=−26.7; 13C{1H} NMR
(DMSO-d6, 101MHz): δ = 170.5 (2C, amide C=O), 97.8, 97.4 (4C, Ar(q)), 88.4 (d,
4C, J= 5.0 Hz, Ar), 87.8 (d, 4C, J = 4.5 Hz, Ar), 70.2 (br, 6C, PTA), 69.7, 69.5, 68.0
(6C, 6 × –CH2–O–), 48.2 (d, 6C, J= 19.5 Hz, PTA), 35.8, 35.1 29.3, 28.2 (8C, 8 ×
CH2), 17.9 (2C, Ar–CH3); HRMS (ES+) m/z found 1173.1698 [M +H]+
C42H69Cl4N8O5P2Ru2 requires 1173.1703; C42H68Cl4N8O5P2Ru2•4HCl (%): calcd
C 38.31 H 5.51 N 8.51; found C 38.43 H 5.55 N 8.36. See Supplementary Fig. 3 for
NMR spectral proﬁles.
RuC10Ox: Ruthenium acid monomer (200 mg, 0.392 mmol) was suspended in
DMF (1.5 ml) under an atmosphere of N2 followed by the addition of DIPEA (137
μl, 0.787 mmol) and TBTU (126 mg, 0.392 mmol). The suspension was stirred for
10 m followed by the addition of 1,10-diaminodecane (16.9 mg, 0.098 mmol) and
left to stir for 2 h. The yellow suspension was then subjected to centrifugation to
isolate the crude product as a solution in DMF. The DMF layer was then added
dropwise to acetone (12 ml) to precipitate a yellow powder that was further washed
with acetone (10 ml) to yield the desired product that was used without further
puriﬁcation (80 mg, 0.069 mmol, 70 %). 1H NMR (D2O, 400MHz): δ = 5.94 (m br,
8H, Ar), 4.58 (s, 12H, PTA), 4.17 (s, 12H, PTA), 3.12 (t, J= 6.5 Hz, 4H, CH2–NH),
2.60 (s br, 8H, CH2-CH2–CO), 2.07 (s, 6H, CH3), 1.39 (p, J = 7.0 Hz, 4H,
CH2–CH2–NH), 1.08–1.25 (m, 12H, alkyl CH2); 31P{1H} NMR (D2O, 162MHz): δ
=−33.4;13C{1H} NMR (D2O, 101MHz): δ = 173.6 (2C, amide C=O), 166.0 (4C,
oxalate C=O), 99.0 (2C, Ar(q)), 96.2 (2C, Ar(q)), 88.6 (d, J= 3.5 Hz, 4C, Ar), 87.7 (d,
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J= 4.0 Hz, 4C, Ar), 70.7 (d, J= 7.0 Hz, 6C, PTA), 48.5 (d, J= 15.5 Hz, 6C, PTA),
39.3, 35.8, 28.7, 2 x 28.3, 28.2, 26.0 (14C, 14 × CH2), 17.4 (2C, 2 × CH3); HRMS
(ES+) m/z found 580.1384 [M + 2H]2+ C46H70N8O10P2Ru2 requires 580.1401. See
Supplementary Fig. 4 for NMR spectral proﬁles.
RuC10Cl4 (C10): RuC10Cl4 was synthesized using previously described
methodology via RuC10Ox18. This entailed slow addition of acetyl chloride (890 μl,
12.5 mmol) to MeOH (5 ml) at 0 °C under an atmosphere of N2. The solution was
allowed to stir for 10 m followed by the addition of RuC10Ox (68 mg, 0.059 mmol)
as a suspension in MeOH (2 ml). A red precipitate instantly formed; the mixture
was stirred for 16 h. The solvent was then decanted and the red residue was washed
with MeOH (2 × 5 ml) then dried under reduced pressure to yield the
hydrochloride salt of the desired product as a red solid (29 mg, 0.023 mmol, 39%).
1H NMR (DMSO-d6, 400MHz): δ = 7.90 (br, 2H, amide NH), 5.81–5.94 (m, 8H,
Ar), 4.69–4.92 (m, 12H, PTA), 4.29 (s, 12H, PTA), 2.98 (m, 4H, 2 × –CH2–NH–),
2.37 (s, 8H, 2 × –CH2–CH2–CO–), 1.91 (s, 6H, 2 × –CH3), 1.33 (m, 4H,
–CH2–CH2–NH–), 1.13–1.24 (m, 12H, 6 x CH2); 31P{1H} NMR (DMSO-d6, 162
MHz): δ =−26.7; 13C{1H} NMR (DMSO-d6, 101MHz): δ = 170.3 (2C, amide
C=O), 2 × 97.8 (4C, Ar(q)), 88.4 (d, J= 4.0 Hz, 4C, Ar), 87.7 (d, J= 5.0 Hz, 4C, Ar),
70.2 (6C, PTA), 48.2 (6C, PTA), 38.4, 35.2, 29.1, 29.0, 28.7, 28.2, 26.4 (14C, 14 ×
CH2), 17.9 (2C, 2 × CH3); HRMS (ES+) m/z found 1125.1792 [M +H]+
C42H69Cl4N8O2P2Ru2 requires 1125.1855; C42H68Cl4N8O2P2Ru2•4HCl (%): calcd
C 39.76 H 5.72 N 8.83; found C 40.00 H 5.74 N 8.53. See Supplementary Fig. 5 for
NMR spectral proﬁles.
Crystallographic analysis of nucleosome core particle. X-ray crystallographic
analysis was conducted using NCP assembled with recombinant Xenopus laevis or
Homo sapiens histones and a 145 bp DNA fragment32. H. sapiens core histone
expression plasmids33 were kindly provided by Hitoshi Kurumizaka (Waseda
University, Japan) and Thirumananseri Kumarevel (RIKEN Harima Institute at
SPring8, Japan). The hanging droplet method was used to grow NCP crystals from
buffers containing MnCl2, KCl and K-cacodylate [pH 6.0]34. Crystals were har-
vested and transferred into a stabilization buffer (37 mM MnCl2, 40 mM KCl, 20
mM K-cacodylate [pH 6.0], 24% 2-methyl-2,4-pentanediol and 2% trehalose).
MgSO4 was substituted in place of MnCl2 by thorough rinsing of crystals with a
magnesium buffer (10 mM MgSO4, 20 mM K-cacodylate [pH 6.0], 24% 2-methyl-
2,4-pentanediol and 2% trehalose)10.
To obtain NCP-binuclear adduct structures, native NCP crystals were subjected
to 15- to 67-h incubation with magnesium buffer containing 1 or 2 mM binuclear
agent (Supplementary Tables 1–4). Treated crystals were mounted directly into a
cryocooling N2 gas stream set at −175 °C7. X-ray diffraction data were recorded at
beam line X06DA of the Swiss Light Source (Paul Scherrer Institute, Villigen,
Switzerland) at an X-ray wavelength of 1.50 Å with a Pilatus 2M-F detector. Data
were processed using MOSFLM35 and SCALA from the CCP4 suite36.
Initial solution of NCP-binuclear adduct structures was achieved by molecular
replacement using the crystal structure of NCP containing RAPTA-C adducts (pdb
code 3MNN)10 as the reference model. Routines from the CCP4 suite36 were used
to conduct structural reﬁnement and model building. Small molecule crystal
structures of the oxalato derivatives of C2, RR, SS and RS18 were used to compose
stereochemical restraint parameters for the binuclear adducts. Data collection and
structural reﬁnement statistics are given in Supplementary Tables 1–4. Molecular
graphics images were produced with PyMOL (DeLano Scientiﬁc LLC, San Carlos,
CA, USA).
Determination of cell growth inhibition parameters. The human cervical car-
cinoma cell line, HeLa, was a gift from Peter Dröge (NTU, Singapore). HeLa cells
were grown at 37 °C and 5% CO2 in DMEM medium containing 10% foetal calf
serum with 2 mM glutamine, 100 units per ml penicillin and 100 μg ml−1 strep-
tomycin. To measure the cytotoxicity from exposure to different agents, cells were
seeded in 96-well plates (5000 cells per well) and grown for 24 h. Stock solutions
were prepared by dissolving cisplatin (purchased from Sigma-Aldrich, USA
(P4394-250MG)), RAPTA-C, C2, C10, PEG or RR in complete medium. These
medium stocks were then subjected to serial dilutions and added to the cells at
various concentrations. Media alone was added to the untreated control cells.
Following a 72 h (IC50 values used for DNA damage analysis) or 40 h (IC50
values used for other experiments) incubation, media were aspirated and 100 µl of
10% 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide in DMEM
complete medium (TOX1-1KT; MTT kit, Sigma-Aldrich) was added to cells, which
were incubated for 3 h at 37 °C. Subsequently, 100 µl of solubilization buffer was
added to each well with vigorous pipetting in order to dissolve the formazan. The
resulting optical density was measured at 570 and 690 nm using a multi-well plate
reader (Inﬁnite M200 PRO, Magellan data analysis software, TECAN, Switzerland).
The ratios of surviving cells were calculated by comparing to the untreated samples,
and the IC50 was derived based on at least three independent measurements.
Binuclear uptake and chromatin adduct quantiﬁcation. Cell culture and binuc-
lear treatment: HeLa cells, obtained from the European Centre of Cell Cultures
(ECACC, Salisbury, UK), were kindly provided by Claudia Battistella (School of
Engineering, EPFL, CH). The cells were maintained in DMEM GlutaMax medium
supplemented with 10% foetal bovine serum and 1% penicillin/streptomycin in a
humidiﬁed environment at 37 °C with 5% CO2. For total cell uptake and chromatin
binding experiments, cells were grown as adherent monolayers in six-well plates or
75 cm2 ﬂasks, respectively, for 24 h prior to drug exposure. Then the cells were
incubated at 37 °C for 24 h with the binuclear compounds in complete culture
medium at a concentration of 100 µM or at the respective IC50 concentration
(Fig. 1). Subsequently, the cells were washed twice with phosphate buffered saline
solution to remove unbound drug and harvested by using an enzyme-free cell
dissociation buffer (Millipore, Switzerland) and pelleted by centrifugation at 100×g
for 4 min. The experiments were performed in triplicate.
Chromatin isolation: Prior to chromatin isolation, a cross-linking reaction using
1% formaldehyde in PBS was performed for 10 min at room temperature and
subsequently quenched by adding 2 M glycine (ﬁnal concentration of 100 mM) for
5 min. The chromatin was extracted using a Pierce Chromatin Prep Module
(Thermo Fisher Scientiﬁc, Switzerland) according to the manufacturer’s protocol.
DNA and protein quantiﬁcation: All chromatin samples were analysed for their
chromosomal DNA content prior to inductively coupled plasma-mass
spectrometry (ICP-MS) measurements. DNA was quantiﬁed by ultraviolet
absorption measurements at 260 nm and with the PicoGreen dsDNA quantitation
assay (Invitrogen). PicoGreen (50 μl per well, 200× diluted in 10 mM Tris + 1 mM
EDTA) was added to 50 μl of DNA sample and the ﬂuorescence signal was
determined by spectroﬂuorometric analysis (484 nm excitation, 520 nm emission)
using an automated reader (SpectraMax5e, Molecular Devices). For total cell
uptake experiments, cell lysis was performed using lysis buffer (Pierce Chromatin
Prep Module, Thermo Fisher Scientiﬁc, Switzerland) and the protein concentration
of aliquots (10 μl per sample) of each lysate was determined by the Bradford
method37 (Bio-Rad Laboratories AG, Switzerland).
Inductively coupled plasma-mass spectrometry measurements: Prior to
determination of ruthenium content, the chromatin extracts or cell lysates were
digested with 400 µl of 69% nitric acid solution overnight at room temperature and
adjusted with ultrapure water to a ﬁnal volume of 4 ml. Metal concentrations were
measured on an ICP-MS instrument (Elan DRC II, Perkin Elmer, Switzerland)
equipped with a Meinhard nebulizer and a cyclonic spray chamber. The ICP-MS
instrument was tuned daily using a solution provided by the manufacturer
containing 1 p.p.b. each of Mg, In, Ce, Ba, Pb and U. 115In was used as an internal
standard at a concentration of 0.5 p.p.b. External standards (ranging from 0.5 p.p.b.
to 20 p.p.b.) were prepared gravimetrically in an identical matrix to the samples
with single element standards (CPI International, Amsterdam, Holland). Three
independent measurements were performed for each sample.
Cell cycle analysis. HeLa cells were seeded into 35 mm six-well plates, incubated
overnight, and the following evening the agents at their respective IC50 con-
centrations (Fig. 1) were added into triplicate samples for 40 h incubation. Sub-
sequently, the medium containing compound was removed and the cells were
collected for cell cycle analysis. Cells were rinsed in PBS, detached with trypsin,
pelleted and washed before they were added in a dropwise manner into 70%
ethanol. After overnight-incubation, cells were washed in PBS and incubated with
DAPI dihydrochloride (3 µM, Life Technologies) for 15 min in the dark before
analysing on a Fortessa ﬂow cytometer (BD FACSDiva software, BD Biosciences).
Analysis of cellular data was based on three independent replicates of each
experiment. Graphic plots were generated with Excel (Microsoft Corporation).
Mahalanobis multivariate analysis38 was carried out using Xlstat (Addinsoft
Corporation).
DNA damage response analysis. HeLa cells were seeded and incubated for 24 h
before the complete media was replaced with either agent-free media or media
containing either cisplatin, RAPTA-C, C10 or RR at their corresponding 72 h-IC50
concentrations (cisplatin, 2.9 ± 0.3 μM; RAPTA-C, 603± 179 μM; C10, 5.8± 1.8
μM; RR, 2.3± 0.4 μM). Cells were grown for 72 h, then washed twice in PBS and
harvested by scraping in ice-cold RIPA buffer containing inhibitors (2 mM PMSF,
8 mM NaF and 1× protease inhibitor cocktail (Roche)). The lysates were sonicated
on ice, three pulses for 10 s on and 10 s off at 35% power. Samples and protein
ladders (Cell Signaling) were run on 4–15% gradient gels (Mini-PROTEAN TGX
cat. no. 456–1084), subsequently, they were wet-transferred onto 0.2 µm pore
nitrocellulose (12369S Cell Signaling Technology) for 1.5 h at 70 V in transfer
buffer containing 20% methanol. The blots were cut into strips and subjected to
blocking with 5% nonfat milk in 1× Tris-buffered saline with Tween 20 detergent
(TBST). Afterwards, each strip was incubated with the antibody corresponding to
the size range of the protein of interest (Cell Signaling Technology (MA, USA)
rabbit antibodies: phospho-Chk1 Ser345 (#2348), phospho-Chk2 Thr68 (#2197),
phospho-histone H2A.X Ser139 (γH2A.X; #9718) and mouse anti-β-actin (#3700)
as a loading control). Subsequently, they were incubated with the secondary anti-
rabbit IgG horseradish peroxidase (HRP)-linked antibody or anti-mouse IgG HRP-
linked antibody (#7074, #7076, respectively, Cell Signaling Technology) and the
bands were visualized using the 3,3′,5,5′-tetramethylbenzidine substrate for HRP
(W4121 Promega, WI, USA). All antibodies were employed at a concentration
corresponding to a 1000-fold dilution over the company-supplied aliquots.
Uncropped western blot scans corresponding to the data shown in Supplementary
Fig. 10 are given in Supplementary Fig. 11.
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Live cell imaging. Transfection of HeLa cells with H2B-EGFP and cell sorting: HeLa
cells were transfected with an H2B-EGFP plasmid39 (plasmid #11680; obtained
from Addgene, Cambridge, USA) using Lipofectamine 2000 reagent (Invitrogen,
USA) according to the company’s protocol. Stable transfectants were obtained by
growing the cells in full growth media supplemented with 500 µg ml−1 G418-sulfate
(Promega). Subsequently, they were subjected to cell sorting; the cells were sepa-
rated into high-expressing, medium-expressing and low-expressing populations
(while the non-expressing cells were discarded). After growing up the different
populations, they were tested for suitability for live imaging. Due to strong
ﬂuorescence and toxicity considerations during long exposure, the low-expressing
population was selected for time-lapse experiments, after it was subjected to an
additional round of sorting, where the non-expressing and high-expressing cells
were eliminated.
Time lapse confocal microscopy: The H2B-EGFP-stably transfected and sorted
HeLa cells were seeded in four out of eight wells of µ-slide eight-well ibiTreat dishes
(80827, Ibidi, Germany). Cells were pre-treated for 16 h with the different drug or
binuclear compounds (or agent-free control) and were then simultaneously imaged
live for 24 h in complete growth DMEM medium without phenol red (31053-028,
Gibco Life Technologies, USA) using a CorrSight confocal spinning disk
microscope (FEI GmbH, Germany) equipped with an Orca R2 CCD camera
(Hamamatsu, Japan) and a complete environmental control system (Ibidi GmbH)
using the multi-stage position function in LA software (FEI GmbH). Time-lapse
imaging was carried out at 37 °C, 5% CO2 and 90% humidity in a closed-
atmosphere chamber. Confocal z-stacks (1 µm z-interval; 20 µm total z-volume)
were acquired with a 40× oil objective (NA 1.3, EC Plan Neoﬂuar M27, Zeiss) every
10 min using the 488 nm laser line (65 mW; iChrome MLE-LFA) and standard
GFP ﬁlter sets. Focus was maintained by a hardware autofocus system
implemented in LA software, focus clamp. To minimize photo damage, the laser
output power was set to 30–40% and a minimal exposure time (typically 100 ms)
was chosen. Due to an additional and differential cytotoxic effect arising from
sustained exposure to the blue laser light, drug and binuclear treatment
concentrations were scaled to give a roughly equivalent number of cell death events
over the course of imaging. This entailed 16 h pre-treatments with either 8 μM
cisplatin, 40 μM RR, 100 μM C10, 600 μM C2, 600 μM PEG or 600 μM RAPTA-C.
Nucleosome array studies. Array DNA production: The nucleosome array DNA
construct19 consists of 36 repeats of the Widom 601 nucleosome core sequence that
is ﬂanked by 30 bp linkers (with the exception of the two termini), inserted into
pUC18 vector. Plasmid was used to transform the DH5α strain of Escherichia coli,
chosen to suppress recombination activities on the plasmid. One single colony was
selected to inoculate 5 ml 2× TY media containing 100 µg ml−1 ampicillin. The
culture was incubated in a shaker incubator at 180 r.p.m., 37 °C, until the media
appeared turbid (3–5 h) and transferred into 2 ﬂasks, each containing 500 ml TB
media with 100 µg ml−1 Ampicillin, which were subsequently incubated at 150 r.p.
m., 37 °C, for 16 h.
Cells were harvested by centrifugation at 8671×g, 20 °C, for 7 min and
resuspended in 20 ml of lysis solution I (50 mM glucose, 10 mM EDTA, 25 mM
Tris-HCl (pH 8.0)). Following addition of 50 mg lysozyme and incubation at room
temperature for 15 min, 40 ml of lysis solution II (0.2 M NaOH, 1% w/v sodium
dodecyl sulfate) was added. After a 5 min incubation on ice, 70 ml of lysis solution
III (4 M K-acetate, 2 M acetic acid) was added. Precipitated cell debris was spun
down at 9000×g, 4 °C, for 20 min and the supernatant was ﬁltered through four
layers of sterile gauze. Nucleic acid was precipitated by adding 0.6× volume of
isopropanol, incubating on ice for 5 min, and centrifuging at 12,000×g, 4 °C, for 20
min. Pellet was dissolved in 10 ml TE(10,10) buffer (10 mM Tris-HCl [pH 8.0], 10
mM EDTA), and 10 ml of 5M LiCl solution was added to precipitate the RNA and
protein. After spinning down at 12,000×g, 20 °C, for 10 min, isopropanol
precipitation was carried out as described above. Pellet was resuspended in 10 ml
TE(10,1) buffer (10 mM Tris-HCl [pH 8.0], 1 mM EDTA), and 50 µl of 10 mgml−1
RNAse A was added. Following a 15 min incubation at room temperature, 0.2×
volume of 4M NaCl and 0.4× volume of 40% PEG 6000 were added. The mixture
was incubated on ice for 30 min and centrifuged at 15,000×g, 4 °C, for 30 min. The
pellet was then dissolved in 5 ml of TE(10,1) buffer, and 3 ml of phenol:chloroform
(1:1 volume ratio) was added to separate plasmid from the remaining protein
contaminants. Sample was centrifuged at 4000×g, 20 °C, for 10 min. The aqueous
layer was collected and ethanol-precipitated. The puriﬁed plasmid pellet was
dissolved in TE(10,1) buffer.
EcoRV digestion of the puriﬁed array plasmid was performed to release insert.
Dra1 and HaeII enzymes were used to cut the vector down into smaller fragments.
PEG precipitation was performed to remove most of the vector fragments. NaCl
solution of 4M and 40% PEG 6000 were added to the plasmid to yield ﬁnal
concentrations of 1–2 mgml−1 DNA, 0.54 M NaCl and 7% PEG 6000. After
incubation on ice for 30 min, the mixture was centrifuged at 10,000×g for 30 min at
4 °C. The pellet was then dissolved in TE(10,1) and assessed by 10%
polyacrylamide gel electrophoresis (PAGE). The PEG precipitation was then
repeated, but with slightly less 40% PEG 6000 added to give a lower ﬁnal
concentration. After repeating this procedure two to three times, the sample would
contain very little or no amount of digested vector fragment. Pure array DNA was
ethanol-precipitated and stored in TE(10,1) buffer at −20 °C.
Nucleosome array reconstitution: The methodology for nucleosome array
reconstitution was modiﬁed from refs. 19, 20, 40 and the online protocol (http://
www.epigenesys.eu/images/stories/protocols/pdf/20111025120327_p42.pdf).
Histone octamer (H. sapiens), in a solution of 10 mM triethanolamine (TEA)-
hydrochloride [pH 7.5], 1 mM EDTA and 2M NaCl, was mixed at different molar
stoichiometry with array DNA (ﬁxed at concentration of 0.1 mgml−1) to determine
the optimal ratio for yielding saturated nucleosome array (Supplementary Fig. 12).
Competitor DNA, consisting of 84/85 bp α-satellite DNA fragment, was added at a
one-half mass-ratio with respect to the array DNA to prevent oversaturation of the
array. A double-bag dialysis system was employed, whereby the sample in one
dialysis bag was ‘dialysed’ against 10 mM TEA-HCl [pH 7.5], 1 mM EDTA and 2
M NaCl in a second dialysis bag, which was in turn dialysed against 10 mM TEA-
HCl [pH 7.5] and 1 mM EDTA. In this way, the reconstitution kinetics were
slowed, and the resulting quality of nucleosome array was consequently improved.
Dialysis was carried out overnight at 4 °C, precipitate was removed by spinning
down at 14,000×g, 4 °C, for 15 min, and the concentration of reconstituted
nucleosome array was calculated based on the DNA concentration. The quality of
the reconstituted nucleosome array was assessed by agarose gel electrophoresis
(0.8% agarose with 0.2× TBE buffer). The saturation of the reconstituted
nucleosome array was conﬁrmed by digesting sample with AvaI enzyme (5000
units per mg DNA; cuts at the center of the linker DNA sections) at 37 °C for 1 h
and then visualizing with 6% PAGE. When required, buffer exchange to 20 mM K-
cacodylate [pH 6.0] was achieved using a 50 kDa-cutoff concentrator device.
Electrophoretic mobility shift analysis: For the derivatization studies,
nucleosome array was maintained at a low, 13 nM, concentration to minimize
precipitation and loss of material through inter-array cross-linking from the
binuclear treatments. Nucleosome array in 20 mM K-cacodylate [pH 6.0] was
incubated for 1 day at room temperature with a range of drug or binuclear
concentrations of up to 46 μM for cisplatin and PEG and up to 230 μM for
RAPTA-C and C2. Samples were subsequently passed through a DyeEx 2.0 spin
column (Qiagen) to remove unbound metallo-compound before analysis by
electrophoretic mobility shift analysis (0.8% agarose with 0.2× TBE buffer).
Electron microscopy: Samples of 13 nM nucleosome array in 20 mM K-
cacodylate [pH 6.0] were incubated for 1 day at room temperature with 46 μM drug
or binuclear agent. Samples were subsequently passed through a DyeEx 2.0 spin
column (Qiagen) to remove unbound metallo-compound. Derivatized and native
samples were diluted to attain 30 µg ml−1 nucleosome array, which was
subsequently dialysed against 10 mM TEA-HCl [pH 7.5], 40 mM NaCl buffer (with
either 0, 0.5 or 1.6 mM MgCl2) at 4 °C overnight. To ﬁx the samples, 2 µl of 25%
glutaraldehyde was added to 98 µl sample buffer to make a 0.5% stock. Two μl of
this solution was then added to 8 µl of sample, so that the ﬁnal glutaraldehyde
concentration was 0.1%, followed by incubation on ice for 10 min.
Continuous carbon-coated grids were freshly prepared and glow-discharged
before use40. Four microlitres of sample were deposited on grids for 1 min, blotted
with ﬁlter paper and negatively stained with 1 drop of 2% (w/v) uranyl acetate
solution. Electron microscopy images were collected on a T12 (FEI) transmission
electron microscope equipped with a 4K Eagle ccd camera (FEI), at 120 keV and
liquid nitrogen temperature. The nominal magniﬁcation was x49,000, calibrated
object pixel size 0.2 nm and a defocus range between 1.0–2.0 µm.
Nucleosome protein binding and cross-linking analysis. RCC1 protein produc-
tion: The gene coding for the Drosophila RCC1 protein inserted into the pST50Tr-
STRaHISNdRCC1t1 plasmid21 was a gift from S. Tan (Penn State, USA). The
RCC1 gene was PCR-ampliﬁed and cloned into the pET28a bacterial expression
vector, with a His-tag followed by a tobacco etch virus cleavage site at the N-
terminus. RCC1 protein was overexpressed in E. coli BL21DE3 cells at reduced
temperature, 18 °C, to maximize protein yields. The cells were harvested and
resuspended in sonication buffer (20 mM Tris-HCl [pH 7.5], 5% glycerol, 500 mM
NaCl, 0.5 mM phenylmethylsulfonyl ﬂuoride and 0.05% (v/v) 1× protease inhibitor
cocktail (Roche)) and then lysed using a homogenizer. The lysate was clariﬁed by
centrifugation at 50,000×g, and the supernatant was loaded onto a 5 ml IMAC-Ni
column pre-equilibrated with 20 mM Tris-HCl [pH 7.5], 5% glycerol, 500 mM
NaCl buffer. The protein was eluted with an imidazole gradient and subjected to
Tobacco Etch Virus (TEV) protease cleavage. After complete TEV digestion, the
sample was passed over an IMAC-Ni column to remove the His-tag. The ﬂow-
through, containing RCC1, was further puriﬁed using a diethylaminoethyl
sepharose fast ﬂow (DEAE FF) ion exchange column (GE Healthcare Life Sci-
ences). Fractions containing RCC1 protein were pooled together, concentrated to 8
mgml−1 and stored at −80 °C.
Protein binding and cross-linking assays: RCC1 binding and cross-linking
analyses were conducted using NCP assembled with H. sapiens histones and a 145
bp DNA fragment32. For the RCC1 experiments, 1 µM NCP, in a buffer of 20 mM
K-cacodylate [pH 6.0], was incubated with 10/20 µM RAPTA-C (Fig. 8a), 100/150
µM RAPTA-C (Fig. 8b), 10/15/20 µM RR, 5/10 µM C2 or 5/10 µM C10 (Fig. 8a) at
room temperature for ~13 h. Native or treated NCP (0.5 µM) were subsequently
incubated with RCC1 (2 µM) in 20 mM K-cacodylate [pH 6.0] buffer on ice for 15
min. The samples were subjected to native PAGE at 4 °C, and gels were stained
with coomassie brilliant blue. For the nucleosome cross-linking experiments, 1 µM
NCP, in a buffer of 20 mM K-cacodylate [pH 6.0], was incubated with 10/20 µM
RAPTA-C, 10/20 µM RR, 10/20 µM C2 or 10/20 µM C10 at room temperature for
24 h. Samples were subsequently analysed with native PAGE, and gels were stained
with coomassie brilliant blue.
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For the analysis of histone protein cross-linking under denaturing conditions, 1
μM NCP, in a buffer of 20 mM K-cacodylate [pH 6.0], was incubated with 10/20
μM RAPTA-C, 10/20 μM RR, 10/20 μM C2 or 10/20 μM C10 at room temperature
overnight. Five microlitres of 5× loading dye (250 mM Tris-HCl [pH 6.8], 10% w/v
sodium dodecyl sulfate (SDS), 25 mM dithiothreitol, 0.1% w/v bromophenol blue,
50% v/v glycerol) was added to the 20 μl reaction mix, followed by a 1 min
incubation at 95 °C. After brief centrifugation, samples were loaded onto a 15%
SDS-PAGE gel, and the gel was subsequently stained with coomassie brilliant blue.
Histone protein identity was assessed by subjecting bands excised from the SDS-
PAGE gel to matrix assisted laser desorption/ionization-time of ﬂight (MALDI-
TOF) mass spectrometry and by western blot analysis. Anti-H2A (ab13923) and
anti-H2B (ab1790) western blotting was performed following the vendor’s protocol
(AbCam, UK; primary antibodies employed at 1000-fold dilution relative to
company-supplied aliquots). The secondary antibody corresponded to HRP-linked
goat pAb anti-rabbit IgG (ab6721) employed at 5000-fold dilution. Data shown in
Supplementary Fig. 14b correspond to uncropped blot scans.
Data availability. Atomic coordinates and structure factors for the NCP models
with RR, SS, RS and C2 adducts have been deposited in the Protein Data Bank
under accession codes 5XF3, 5XF4, 5XF5 and 5XF6, respectively. Other data that
support the ﬁndings of this study are available from the corresponding authors
upon request.
Received: 17 April 2017 Accepted: 9 October 2017
References
1. McGinty, R. K. & Tan, S. Nucleosome structure and function. Chem. Rev. 115,
2255–2273 (2015).
2. Avgustinova, A. & Benitah, S. A. The epigenetics of tumour initiation: cancer
stem cells and their chromatin. Curr. Opin. Genet. Dev. 36, 8–15 (2016).
3. Sharma, S., Kelly, T. K. & Jones, P. A. Epigenetics in cancer. Carcinogenesis 1,
27–36 (2010).
4. Bowman, G. D. & Poirier, M. G. Post-translational modiﬁcations of histones
that inﬂuence nucleosome dynamics. Chem. Rev. 115, 2274–2295 (2015).
5. Segal, E. & Widom, J. From DNA sequence to transcriptional behaviour: a
quantitative approach. Nat. Rev. Genet. 10, 443–456 (2009).
6. Davey, C. A. Exposure to metals can be therapeutic. Chimia 69, 125–130
(2015).
7. Adhireksan, Z. et al. Ligand substitutions between ruthenium-cymene
compounds can control protein versus DNA targeting and anticancer activity.
Nat. Commun. 5, 3462 (2014).
8. Ma, Z. et al. An organometallic compound which exhibits a DNA topology-
dependent one-stranded intercalation mode. Angew. Chem. Int. Ed. Engl. 55,
7441–7444 (2016).
9. Adhireksan, Z. et al. Allosteric cross-talk in chromatin can mediate drug-drug
synergy. Nat. Commun. 8, 14860 (2017).
10. Wu, B. et al. A ruthenium antimetastasis agent forms speciﬁc histone protein
adducts in the nucleosome core. Chem. Eur. J. 17, 3562–3566 (2011).
11. Meier, S. M. et al. Novel metal(II) arene 2-pyridinecarbothioamides: a rationale
to orally active organometallic anticancer agents. Chem. Sci. 4, 1837–1846
(2013).
12. Merlino, A. Interactions between proteins and Ru compounds of medicinal
interest: a structural perspective. Coord. Chem. Rev. 326, 111–134 (2016).
13. Scolaro, C. et al. In vitro and in vivo evaluation of ruthenium(II)-arene PTA
complexes. J. Med. Chem. 48, 4161–4171 (2005).
14. Nowak-Sliwinska, P. et al. Organometallic ruthenium(II) arene compounds
with antiangiogenic activity. J. Med. Chem. 54, 3895–3902 (2011).
15. Weiss, A. et al. In vivo anti-tumor activity of the organometallic ruthenium(II)-
arene complex [Ru(eta(6)-p-cymene)-Cl-2(pta)] (RAPTA-C) in human ovarian
and colorectal carcinomas. Chem. Sci. 5, 4742–4748 (2014).
16. McGinty, R. K. & Tan, S. Recognition of the nucleosome by chromatin factors
and enzymes. Curr. Opin. Struct. Biol. 37, 54–61 (2016).
17. Kalashnikova, A. A., Porter-Goff, M. E., Muthurajan, U. M., Luger, K. &
Hansen, J. C. The role of the nucleosome acidic patch in modulating higher
order chromatin structure. J. R. Soc. Interface 10, 20121022 (2013).
18. Murray, B. S., Menin, L., Scopelliti, R. & Dyson, P. J. Conformational control of
anticancer activity: the application of arene-linked dinuclear ruthenium(II)
organometallics. Chem. Sci. 5, 2536–2545 (2014).
19. Robinson, P. J., Fairall, L., Huynh, V. A. & Rhodes, D. EM measurements deﬁne
the dimensions of the "30-nm" chromatin ﬁber: evidence for a compact,
interdigitated structure. Proc. Natl Acad. Sci. USA 103, 6506–6511 (2006).
20. Routh, A., Sandin, S. & Rhodes, D. Nucleosome repeat length and linker
histone stoichiometry determine chromatin ﬁber structure. Proc. Natl Acad. Sci.
USA 105, 8872–8877 (2008).
21. Makde, R. D., England, J. R., Yennawar, H. P. & Tan, S. Structure of RCC1
chromatin factor bound to the nucleosome core particle. Nature 467, 562–566
(2010).
22. Wolters, D. A., Stefanopoulou, M., Dyson, P. J. & Groessl, M. Combination of
metallomics and proteomics to study the effects of the metallodrug RAPTA-T
on human cancer cells. Metallomics 4, 1185–1196 (2012).
23. Berndsen, R. H. et al. Combination of ruthenium(II)-arene complex [Ru(η6-p-
cymene)Cl2(pta)] (RAPTA-C) and the epidermal growth factor receptor
inhibitor erlotinib results in efﬁcient angiostatic and antitumor activity. Sci.
Rep. 7, 43005 (2017).
24. Chodaparambil, J. V. et al. A charged and contoured surface on the nucleosome
regulates chromatin compaction. Nat. Struct. Mol. Biol. 14, 1105–1107 (2007).
25. Zhou, J., Fan, J. Y., Rangasamy, D. & Tremethick, D. J. The nucleosome surface
regulates chromatin compaction and couples it with transcriptional repression.
Nat. Struct. Mol. Biol. 14, 1070–1076 (2007).
26. Barbera, A. J. et al. The nucleosomal surface as a docking station for Kaposi's
sarcoma herpesvirus LANA. Science 311, 856–861 (2006).
27. Fang, Q. et al. Human cytomegalovirus IE1 protein alters the higher-order
chromatin structure by targeting the acidic patch of the nucleosome. Elife 5,
e11911 (2016).
28. Hanif, M. et al. The functionalization of RuII(η6-p-cymene)(3-hydroxy-2-
pyridone) complexes with (Thio)morpholine: synthesis and bioanalytical
studies. Chempluschem 82, 841–847 (2017).
29. Luger, K., Mader, A. W., Richmond, R. K., Sargent, D. F. & Richmond, T. J.
Crystal structure of the nucleosome core particle at 2.8 Å resolution. Nature
389, 251–260 (1997).
30. Dorigo, B. et al. Nucleosome arrays reveal the two-start organization of the
chromatin ﬁber. Science 306, 1571–1573 (2004).
31. Song, F. et al. Cryo-EM study of the chromatin ﬁber reveals a double helix
twisted by tetranucleosomal units. Science 344, 376–380 (2014).
32. Ong, M. S., Richmond, T. J. & Davey, C. A. DNA stretching and extreme
kinking in the nucleosome core. J. Mol. Biol. 368, 1067–1074 (2007).
33. Tanaka, Y. et al. Expression and puriﬁcation of recombinant human histones.
Methods 33, 3–11 (2004).
34. Davey, C. A., Sargent, D. F., Luger, K., Maeder, A. W. & Richmond, T. J.
Solvent mediated interactions in the structure of the nucleosome core particle at
1.9 Å resolution. J. Mol. Biol. 319, 1097–1113 (2002).
35. Leslie, A. G. The integration of macromolecular diffraction data. Acta
Crystallogr. D Biol. Crystallogr 62, 48–57 (2006).
36. Bailey, S. The CCP4 suite: programs for protein crystallography. Acta
Crystallogr. D Biol. Crystallogr 50, 760–763 (1994).
37. Bradford, M. M. A rapid and sensitive method for the quantitation of
microgram quantities of protein utilizing the principle of protein-dye binding.
Anal. Biochem. 72, 248–254 (1976).
38. Mahalanobis, P. C. On the generalised distance in statistics. Proc. Natl Inst. Sci.
India 2, 49–55 (1936).
39. Kanda, T., Sullivan, K. F. & Wahl, G. M. Histone-GFP fusion protein enables
sensitive analysis of chromosome dynamics in living mammalian cells. Curr.
Biol. 8, 377–385 (1998).
40. Huynh, V. A., Robinson, P. J. & Rhodes, D. A method for the in vitro
reconstitution of a deﬁned "30 nm" chromatin ﬁbre containing stoichiometric
amounts of the linker histone. J. Mol. Biol. 345, 957–968 (2005).
Acknowledgements
We thank M. Wang, V. Olieric and staff at the Swiss Light Source (Paul Scherrer
Institute, Villigen, Switzerland). We thank H. Kurumizaka and T.S. Kumarevel for
providing us with the human core histone expression plasmids, S. Tan for the RCC1
plasmid, P. Dröge and C. Battistella for HeLa cells, A. Routh for cloning the nucleosome
array and A. Wong for help with EM imaging. The H2B-EGFP plasmid was a gift from
G. Wahl. We are grateful for ﬁnancial support by the Singapore Ministry of Education
Academic Research Fund Tier 3 Programme (grant MOE2012-T3-1-001), Ministry of
Health National Medical Research Council (grant NMRC/1312/2011) and the NTU
Institute of Structural Biology. This research was also supported by the Swiss National
Science Foundation via individual grant no. 200020-140865, the NCCR in Chemical
Biology and by start-up funding from the University of Hull (UK).
Author contributions
G.E.D. conducted the cell growth inhibition and cell cycle assays, confocal time lapse
microscopy, DNA damage marker tests and contributed to manuscript writing; Z.A.
carried out the electrophoretic and EM nucleosome array studies and contributed to the
crystal structure work; Z.M. conducted the X-ray crystallographic analysis and con-
tributed to the electrophoretic analysis of array; T.R. performed the cellular uptake and
chromatin-binding studies; D.S. carried out the nucleosome cross-linking and RCC1-
binding analyses; S.P. set up our human core histone production platform and produced
RCC1 protein; D.R. provided the nucleosome array construct and expertise for producing
the array; A.L. provided expertise for confocal microscopy; S.S. provided expertise for the
ARTICLE NATURE COMMUNICATIONS | DOI: 10.1038/s41467-017-01680-4
12 NATURE COMMUNICATIONS |8:  1575 |DOI: 10.1038/s41467-017-01680-4 |www.nature.com/naturecommunications
EM analysis; B.S.M. and P.J.D. designed and synthesized the binuclear compounds; C.A.
D. designed the study, conducted data analysis and wrote the manuscript.
Additional information
Supplementary Information accompanies this paper at doi:10.1038/s41467-017-01680-4.
Competing interests: The authors declare no competing ﬁnancial interests.
Reprints and permission information is available online at http://npg.nature.com/
reprintsandpermissions/
Publisher's note: Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional afﬁliations.
Open Access This article is licensed under a Creative Commons
Attribution 4.0 International License, which permits use, sharing,
adaptation, distribution and reproduction in any medium or format, as long as you give
appropriate credit to the original author(s) and the source, provide a link to the Creative
Commons license, and indicate if changes were made. The images or other third party
material in this article are included in the article’s Creative Commons license, unless
indicated otherwise in a credit line to the material. If material is not included in the
article’s Creative Commons license and your intended use is not permitted by statutory
regulation or exceeds the permitted use, you will need to obtain permission directly from
the copyright holder. To view a copy of this license, visit http://creativecommons.org/
licenses/by/4.0/.
© The Author(s) 2017
NATURE COMMUNICATIONS | DOI: 10.1038/s41467-017-01680-4 ARTICLE
NATURE COMMUNICATIONS |8:  1575 |DOI: 10.1038/s41467-017-01680-4 |www.nature.com/naturecommunications 13
